Publication | Closed Access

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Fortify Maintenance TrialRheumatologyWithdrawal Phase 3GastroenterologyTreatment OptionClinical GastroenterologyUlcerative ColitisMedicineRheumatoid ArthritisActive Crohn